Blinatumomab | Health Canada Patents | Expiry | Expiration | Dates | PharmaCompass.com

Please Wait

Applying Filters...

Grow Your Pharma Business Digitally

Find Suppliers : API/FDF
- Search Our Integrated Database
Services
Excipients
CDMO Prospector
- Demo Dashboard
Drugs in Dev.
News
Blog
Market Place
Login

Blinatumomab
Health Canada Patents

Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.

Contact Supplier

IOL Chemicals is an innovation-driven bulk drug, Intermediate and Specialty Chemicals company.

Contact Supplier

IKF/Pharmasynthese have been with fine chemicals market and APIs performance for more than 40 years.

Contact Supplier

medac CDMO: Tailored CDMO services for injectables in syringes, cartridges & vials – aseptic, reliable, flexible and a solution ahead.

Contact Supplier

Coral

Contact Supplier

ICE Pharma offers a unique range of bile acid products and best-in-class services for the pharmaceutical industry.

Contact Supplier

Blinatumomab

ACCESS ALL DATA, CHEMISTRY

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

DEVELOPMENTS

60 Drugs in Development

60 Drugs in Development

FINISHED DOSAGE FORMULATIONS

16 FDF Dossiers, 1 FDA Orange Book, 3 Europe, 1 Canada, 10 Australia, 1 South Africa

16 FDF Dossiers
1 FDA Orange Book
3 Europe
1 Canada
10 Australia
1 South Africa

DIGITAL CONTENT

24 News #PharmaBuzz

24 News #PharmaBuzz

GLOBAL SALES INFORMATION

1 US Medicaid Prescriptions, 18 Annual Reports

1 US Medicaid Prescriptions
18 Annual Reports

PATENTS & EXCLUSIVITIES

6 Health Canada Patents

6 Health Canada Patents

Xls

Filters

Reset all filters

Filters

FILTER :

filter Company Reset all filters

6 All

01 6Amgen Canada Inc.

filter Patent Reset all filters

6 All

01 12326389

02 12544532

03 12633594

04 12742242

05 12742249

06 12774919

filter Product Reset all filters

6 All

01 6BLINATUMOMAB

filter Dosage Reset all filters

6 All

01 6POWDER FOR SOLUTION

filter Exp Date Reset all filters

6 All

01 12019-04-21

02 12024-11-26

03 12026-11-29

04 22029-11-06

05 12030-10-27

Product Main Page

01

Amgen Canada Inc.

BLINATUMOMAB

PackExpo

Not Confirmed

Amgen Canada Inc.

PackExpo

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2019-04-21

Date Granted : 2007-01-23

BLINATUMOMAB

Brand Name : BLINCYTO

Patent Number : 2326389

Filing Date : 1999-04-21

Strength per Unit : 38.5 mcg / vial

Dosage Form : POWDER FOR SOLUTION

Human Or VET : Human

Route of Administration : INTRAVENOUS

Patent Expiration Date : 2019-04-21

Date Granted : 2007-01-23

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

02

Amgen Canada Inc.

BLINATUMOMAB

PackExpo

Not Confirmed

Amgen Canada Inc.

PackExpo

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2024-11-26

Date Granted : 2015-06-16

BLINATUMOMAB

Brand Name : BLINCYTO

Patent Number : 2544532

Filing Date : 2004-11-26

Strength per Unit : 38.5 mcg / vial

Dosage Form : POWDER FOR SOLUTION

Human Or VET : Human

Route of Administration : INTRAVENOUS

Patent Expiration Date : 2024-11-26

Date Granted : 2015-06-16

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

03

Amgen Canada Inc.

BLINATUMOMAB

PackExpo

Not Confirmed

Amgen Canada Inc.

Country

PackExpo

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2029-11-06

Date Granted : 2020-07-21

BLINATUMOMAB

Brand Name : BLINCYTO

Patent Number : 2742249

Filing Date : 2009-11-06

Strength per Unit : 38.5 mcg / vial

Dosage Form : POWDER FOR SOLUTION

Human Or VET : Human

Route of Administration : INTRAVENOUS

Patent Expiration Date : 2029-11-06

Date Granted : 2020-07-21

Portfolio PDF

Product Web Link

Virtual Booth

Digital Content

Website

Corporate PDF

04

Amgen Canada Inc.

BLINATUMOMAB

PackExpo

Not Confirmed

Amgen Canada Inc.

Country

PackExpo

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2026-11-29

Date Granted : 2021-10-26

BLINATUMOMAB

Brand Name : BLINCYTO

Patent Number : 2633594

Filing Date : 2006-11-29

Strength per Unit : 38.5 mcg / vial

Dosage Form : POWDER FOR SOLUTION

Human Or VET : Human

Route of Administration : INTRAVENOUS

Patent Expiration Date : 2026-11-29

Date Granted : 2021-10-26

Portfolio PDF

Product Web Link

Virtual Booth

Digital Content

Website

Corporate PDF

05

Amgen Canada Inc.

BLINATUMOMAB

PackExpo

Not Confirmed

Amgen Canada Inc.

Country

PackExpo

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2030-10-27

Date Granted : 2022-03-08

BLINATUMOMAB

Brand Name : BLINCYTO

Patent Number : 2774919

Filing Date : 2010-10-27

Strength per Unit : 38.5 mcg / vial

Dosage Form : POWDER FOR SOLUTION

Human Or VET : Human

Route of Administration : INTRAVENOUS

Patent Expiration Date : 2030-10-27

Date Granted : 2022-03-08

Portfolio PDF

Product Web Link

Virtual Booth

Digital Content

Website

Corporate PDF

06

Amgen Canada Inc.

BLINATUMOMAB

PackExpo

Not Confirmed

Amgen Canada Inc.

Country

PackExpo

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2029-11-06

Date Granted : 2023-01-10

BLINATUMOMAB

Brand Name : BLINCYTO

Patent Number : 2742242

Filing Date : 2009-11-06

Strength per Unit : 38.5 mcg / vial

Dosage Form : POWDER FOR SOLUTION

Human Or VET : Human

Route of Administration : INTRAVENOUS

Patent Expiration Date : 2029-11-06

Date Granted : 2023-01-10

Portfolio PDF

Product Web Link

Virtual Booth

Digital Content

Website

Corporate PDF

Contact us
to update this info

Privacy policy
Terms and conditions
Disclaimers
Ask Us!